A carregar...
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
BACKGROUND: There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1). METHODS: Through a literature-based approach, we discuss mechanisms of resist...
Na minha lista:
| Publicado no: | Breast Cancer Res |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6995165/ https://ncbi.nlm.nih.gov/pubmed/32005279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-1252-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|